Corticosteroids for Guillain-Barré syndrome

Area of Science:

• Neurology
• Immunology

Background:

• Guillain-Barré syndrome (GBS) involves peripheral nerve inflammation, suggesting potential benefit from corticosteroids.
• The efficacy of corticosteroids in GBS treatment remains an area of investigation.

Purpose of the Study:

• To systematically review randomized controlled trials evaluating corticosteroid efficacy in Guillain-Barré syndrome.
• To assess the impact of corticosteroids on recovery speed, disability, and long-term outcomes in GBS patients.

Main Methods:

• Searched multiple databases (Cochrane, MEDLINE, EMBASE) up to June 2009 for relevant trials.
• Included quasi-randomized or randomized controlled trials of corticosteroids or adrenocorticotrophic hormone.
• Primary outcome: change in disability grade after four weeks; secondary outcomes: recovery time, ventilation, mortality, relapse, and adverse events.

Main Results:

• Six trials with 587 participants showed no significant difference in disability grade change after four weeks with corticosteroids compared to controls (moderate quality evidence).
• Oral corticosteroids were associated with significantly less improvement (moderate quality evidence), while intravenous corticosteroids showed no significant difference.
• No significant differences were observed in secondary efficacy outcomes; however, diabetes incidence increased, and hypertension decreased with corticosteroid use.

Conclusions:

• Corticosteroids administered alone do not significantly accelerate recovery or alter long-term outcomes in Guillain-Barré syndrome (moderate quality evidence).
• Low-quality evidence suggests oral corticosteroids may delay recovery.
• Corticosteroid use was linked to a higher incidence of diabetes requiring insulin and a lower incidence of hypertension.